Aberrant activation of intracellular signalling pathways confers malignant properties on
cancer cells. Targeting intracellular signalling pathways has been a productive strategy for …

Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …

Purpose We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in
Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term …

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic
Myeloid Leukemia Page 1 JOURNAL OF CLINICAL ONCOLOGY ORIGINAL REPORT Long-Term …

Background Chronic graft-versus-host disease (GVHD) is the leading cause of later illness
and death after allogeneic hematopoietic stem-cell transplantation. We hypothesized that …

Protein kinases play a predominant regulatory role in nearly every aspect of cell biology and
they can modify the function of a protein in almost every conceivable way. Protein …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …

Abstract STOP second generation (2G)–tyrosine kinase inhibitor (TKI) is a multicenter
observational study designed to evaluate 2G-TKI discontinuation in chronic myeloid …